Aberdeen Group Reduces ADMA Biologics Stake

Institutional investor trims position in biotech company by 13.6% in Q4

Apr. 7, 2026 at 7:04am

Got story updates? Submit your updates here. ›

An extreme close-up of metallic pharmaceutical manufacturing equipment, conveying a sense of industrial power and financial stability without any text or identifiable elements.A major institutional investor's reduced stake in the biotech firm ADMA Biologics reflects broader shifts in the financial landscape surrounding specialized pharmaceutical companies.Ramsey Today

Aberdeen Group plc, an institutional investor, reduced its stake in ADMA Biologics Inc. (NASDAQ:ADMA) by 13.6% in the fourth quarter of 2025, according to a recent SEC filing. The firm now owns 963,949 shares of the biotechnology company's stock, worth approximately $17.6 million.

Why it matters

ADMA Biologics is a biopharmaceutical company focused on developing and commercializing specialty plasma-derived biologics. Changes in major institutional ownership can signal shifts in investor sentiment and impact the stock price.

The details

According to the SEC disclosure, Aberdeen Group sold 152,363 ADMA Biologics shares during the fourth quarter, reducing its total position to 963,949 shares. The firm now owns approximately 0.41% of ADMA's outstanding stock.

  • Aberdeen Group filed the 13F disclosure with the SEC on April 7, 2026, reporting its Q4 2025 holdings.

The players

Aberdeen Group plc

An institutional investor and asset management firm based in the United Kingdom.

ADMA Biologics Inc

A biopharmaceutical company focused on developing and commercializing specialty plasma-derived biologics.

Got photos? Submit your photos here. ›

The takeaway

This filing indicates that a major institutional investor has reduced its position in ADMA Biologics, which could impact the stock price and sentiment around the company. Investors will likely monitor any further changes in institutional ownership of ADMA shares.